Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOBT NASDAQ:MIRA NASDAQ:ONCY NASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOBTIO Biotech$1.95+9.6%$1.77$0.66▼$2.79N/A0.418.85 million shs1.69 million shsMIRAMIRA Pharmaceuticals$1.40+1.4%$1.47$0.73▼$2.56$26.70M1.75180,654 shs135,131 shsONCYOncolytics Biotech$1.06-1.9%$1.04$0.33▼$1.53$106.38M1.19712,671 shs269,926 shsSRZNSurrozen$12.20-2.0%$10.00$5.90▼$18.17$104.56M0.6217,021 shs10,581 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOBTIO Biotech0.00%+23.42%+3.17%+21.88%+101.93%MIRAMIRA Pharmaceuticals0.00%+2.19%+2.19%0.00%-17.65%ONCYOncolytics Biotech0.00%+1.92%+15.83%+194.44%+4.95%SRZNSurrozen0.00%+0.08%+35.11%+43.53%+19.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOBTIO Biotech$1.95+9.6%$1.77$0.66▼$2.79N/A0.418.85 million shs1.69 million shsMIRAMIRA Pharmaceuticals$1.40+1.4%$1.47$0.73▼$2.56$26.70M1.75180,654 shs135,131 shsONCYOncolytics Biotech$1.06-1.9%$1.04$0.33▼$1.53$106.38M1.19712,671 shs269,926 shsSRZNSurrozen$12.20-2.0%$10.00$5.90▼$18.17$104.56M0.6217,021 shs10,581 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOBTIO Biotech0.00%+23.42%+3.17%+21.88%+101.93%MIRAMIRA Pharmaceuticals0.00%+2.19%+2.19%0.00%-17.65%ONCYOncolytics Biotech0.00%+1.92%+15.83%+194.44%+4.95%SRZNSurrozen0.00%+0.08%+35.11%+43.53%+19.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOBTIO Biotech 3.33Buy$8.00310.26% UpsideMIRAMIRA Pharmaceuticals 3.50Strong Buy$17.001,114.29% UpsideONCYOncolytics Biotech 2.80Moderate Buy$5.00371.70% UpsideSRZNSurrozen 3.00Buy$38.50215.57% UpsideCurrent Analyst Ratings BreakdownLatest MIRA, SRZN, ONCY, and IOBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.008/12/2025IOBTIO BiotechMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $4.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ASRZNSurrozen$10.65M9.82N/AN/A($6.55) per share-1.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOBTIO Biotech-$95.49M-$1.58N/AN/AN/AN/A-281.82%-169.29%11/11/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.49N/AN/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)SRZNSurrozen-$63.56M-$14.42N/AN/AN/A-274.42%-545.43%-64.40%11/5/2025 (Estimated)Latest MIRA, SRZN, ONCY, and IOBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IOBTIO Biotech-$0.35-$0.40-$0.05-$0.40N/AN/A8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/A8/8/2025Q2 2025SRZNSurrozen-$1.23-$1.14+$0.09$2.55N/A$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIOBTIO BiotechN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOBTIO Biotech4.221.961.96MIRAMIRA PharmaceuticalsN/A2.802.80ONCYOncolytics BiotechN/A2.882.88SRZNSurrozenN/A16.4116.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOBTIO Biotech54.76%MIRAMIRA Pharmaceuticals35.16%ONCYOncolytics Biotech6.82%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipIOBTIO Biotech4.80%MIRAMIRA Pharmaceuticals6.65%ONCYOncolytics Biotech0.10%SRZNSurrozen45.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOBTIO Biotech30N/AN/ANot OptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionableSRZNSurrozen808.57 million4.70 millionNot OptionableMIRA, SRZN, ONCY, and IOBT HeadlinesRecent News About These CompaniesSurrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4 at 4:15 PM | globenewswire.com5AM Venture Management LLC Acquires Shares of 310,000 Surrozen, Inc. $SRZNSeptember 4 at 7:52 AM | marketbeat.comRA Capital Management L.P. Buys 396,550 Shares of Surrozen, Inc. $SRZNSeptember 4 at 7:02 AM | marketbeat.comSurrozen to Present at Upcoming Healthcare Investor ConferenceSeptember 3, 2025 | globenewswire.comNantahala Capital Management LLC Buys 33,504 Shares of Surrozen, Inc. $SRZNSeptember 3, 2025 | marketbeat.comDriehaus Capital Management LLC Makes New Investment in Surrozen, Inc. $SRZNSeptember 2, 2025 | marketbeat.comInstitutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the companyAugust 30, 2025 | uk.finance.yahoo.comHeights Capital Management Inc. Takes $524,000 Position in Surrozen, Inc. $SRZNAugust 30, 2025 | marketbeat.comSurrozen to Present at Upcoming Healthcare Investor ConferenceAugust 28, 2025 | globenewswire.comStonepine Capital Management LLC Boosts Stake in Surrozen, Inc. $SRZNAugust 26, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Surrozen EarningsAugust 16, 2025 | marketbeat.comSurrozen (NASDAQ:SRZN) Issues Earnings ResultsAugust 11, 2025 | marketbeat.comVivo Capital LLC Takes Position in Surrozen, Inc. (NASDAQ:SRZN)August 9, 2025 | marketbeat.comSurrozen (NASDAQ:SRZN) Stock Price Down 12.8% - Should You Sell?August 9, 2025 | marketbeat.comSurrozen’s Q2 2025: Progress in Eye Disease TherapiesAugust 8, 2025 | tipranks.comSurrozen Reports Q2 Profit on GainsAugust 8, 2025 | fool.comSurrozen Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 8, 2025 | globenewswire.comSurrozen to Present at Upcoming Healthcare Investor ConferenceAugust 6, 2025 | globenewswire.comWe Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthJuly 1, 2025 | finance.yahoo.comDown -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundMay 16, 2025 | zacks.comSurrozen secures patent for tissue repair technologyMay 15, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRA, SRZN, ONCY, and IOBT Company DescriptionsIO Biotech NASDAQ:IOBT$1.95 +0.17 (+9.55%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.77%) As of 09/5/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.MIRA Pharmaceuticals NASDAQ:MIRA$1.40 +0.02 (+1.45%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.40 +0.00 (+0.29%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Oncolytics Biotech NASDAQ:ONCY$1.06 -0.02 (-1.85%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.08 +0.02 (+2.36%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Surrozen NASDAQ:SRZN$12.20 -0.25 (-2.01%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.30 +0.10 (+0.82%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
